Bioresorbable Scaffolds

Prof. Patrick W. Serruys is a professor of Interventional Cardiology at the Interuniversity Cardiological Institute of the Netherlands (1988-1998), and Erasmus MC. Since 1980 he was a Director of the Clinical Research Program of the Catheterization Laboratory, Thorax Center at Erasmus University, and till April 1st 2014 (retirement date) the Head of the Interventional Department, Thorax Center, Erasmus MC (University Medical Center Rotterdam), Rotterdam, The Netherlands. He is a Fellow of the American College of Cardiology and a Fellow of the European Society of Cardiology and scientific council of the International College of Angiology. In 1996 he received the TCT Career Achievement Award and in 1997 he was awarded the Wenkebach Prize of the Dutch Heart Foundation. In 2000 he was awarded the Gruentzig Award of the European Society of Cardiology. In 2001 he held the Paul Dudley White Lecture at the American Heart Association in the USA. In 2004 he received the Andreas Gruentzig Award of the Swiss Society of Cardiology. In 2005 he held the 4th International Lecture at the AHA and Mikamo Lecture at the Japanese heart Association. In 2006 he received the highest award of the Clinical Council of the American Heart Association: the James Herrick Award. In 2007 he received the Arrigo Recordati International Prize (Italy) and the ICI Achievement Award (bestowed by the President of Israel – Shimon Perez). In 2008 he received the Einthoven Penning (Leiden). In 2009 he became Doctor Honoris Causa from the University of Athens. In 2011 he received the Lifetime Achievement Award, bestowed by the American College of Cardiology, in recognition of many years of service and invaluable contributions to the ACC. At the end of 2011 Prof. Serruys received the Ray C. Fish Award, bestowed by the Texas Heart Institute, for outstanding achievement and contribution to cardiovascular medicine. In 2012 he received a Golden Medal of the European Society of Cardiology. In 2013 he became Doctor Honoris Causa from the Complutense University of Madrid.

• Section 1: Introduction 1.1- Early development of bioresorbable scaffold Section 2: Principles of bioresorption, vascular application 2.1- Degradable, biodegradable and bioresorbable polymers for time-limited therapy 2.2- Lactic acid-based polymers in depth 2.3- Scaffold processing 2.4- Basics of biodegradation of magnesium 2.5- Basics of biodegradation of iron scaffold Section 3: From bench test to preclinical assessment 3.1- Unlocking scaffold mechanical properties 3.2- Bench testing for polymeric bioresorbable scaffolds 3.3- Bench test for magnesium scaffold 3.4- Simulation of flow and shear stress 3.5- Preclinical assessment of bioresorbable scaffolds and regulatory implication Section 4: Lesson learned from preclinical assessment 4.1- PLA scaffold 4.2- Iron Section 5: Imaging to evaluate the bioresorbable scaffold: A corelab perspective, methodology of measurement and assessment 5.1- Quantative coronary angiography of bioresorbable vascular scaffold: a corelab perspective 5.2- Assessment of bioresorbable scaffolds by IVUS: echogenicity, virtual histology and palpography 5.3- Optical coherence tomography analysis vascular scaffold in comparison with metallic stents: a corelab perspective 5.4- Non-invasive coronary tomography analysis after bioresorbable scaffold implantation 5.5- Angiography is sufficient 5.6- Intravascular ultrasound is a must in bioresorbable scaffold implantation 5.7- OCT is the way to go 5.8- Imaging to evaluate the bioresorbable scaffold. Clinician's perspective: I need both (IVUS and OCT) 5.9- Multislice computed tomography as a modality of follow-up Section 6: Clinical evidence of randomised and non-randomised trials: personal perspective 6.1- What are appropriate clinical endpoints? From device failure assessment to angina evaluation 6.2- Angina reduction after BRS implantation: correlation with changes in coronary haemodynamics 6.3- Comparison of everolimus eluting bioresorbable scaffolds with everolimus eluting metallic stents for treatment of coronary artery stenosis: Three-year follow-up of the Absorb II randomized trial 6.4- The ABSORB China trial 6.5- ABSORB Japan 6.6- What have we learned from meta-analysis of 1 year outcomes with the Absorb bioresorbable scaffold in patients with coronary heart disease 6.7- Summary of investigator-driven registries on absorb bioresorbable vascular scaffolds 6.8- Investigator-driven randomised trials 6.9- The DESolve scaffold 6.10- Results of clinical trials with BIOTRONIK magnesium scaffolds 6.11- The REVA medical program: from ReZolve (R) to Fantom (R) 6.12- The Amaranth's bioresorbable vascular scaffold technology 6.13- The mirage microfiber sirolimus eluting coronary scaffold 6.14- The Igaki-Tamai stent: the legacy of the work of Hideo Tamai Section 7: Clinical evidence in specific patient subsets: personal perspective 7.1- Left main interventions with BRS 7.2- Bioresorbable scaffolds in bifurcations 7.3- BVS in chronic total occlusions: clinical evidence, tips and tricks 7.4- Bioresorbable scaffolds in diffuse disease 7.5- Bioresorbable scaffolds in mulitvessel coronary disease 7.6- Bioresorbable coronary scaffolds in non-St elevation acute coronary syndromes 7.7- Bioresorbable vascular scaffold in ST-segment elevation myocardial infarction: clinical evidence, tips and tricks 7.8- Bioresorbable scaffolds for treating coronary artery disease in patients with diabetes mellitus 7.9- BRS in calcified lesions 7.10- BRS textbook: invasive sealing of vulnerable, high-risk lesions Section 8: Complications (incidence, diagnosis, potential mechanisms and treatment) 8.1- Acute and subacute scaffold thrombosis 8.2- Late and very late scaffold thrombosis 8.3- Treatment of bioresorbable scaffold failure 8.4- Recoil and bioresorbable scaffolds 8.5- Scaffold disruption and late discontinuities 8.6- The incidence, potential mechanism of side-branch occlusion after implantation of bioresorbable scaffold(s): insights from ABSORB II Section 9: Tips and tricks to implant BRS 9.1- Tips and tricks for implanting BRS: sizing, pre- and post-dilatation 9.2- Approach to bifurcation lesions Section 10: Emerging technologies (pre-CE mark, pre-FA, pre-PMDA and pre-CFDA) 10.1- Overview of the field 10.2- MeRes100 (TM)- a sirolimus eluting bioresorbable vascular scaffold system 10.3- XINSORB bioresorbable vascular scaffold 10.4- NeoVas (TM) bioresorbable coronary scaffold system 10.5- ArterioSorb (TM) bioresorbable scaffold by Arterius Ltd 10.6- Lifetech 10.7- Abbott: new generation absorb scaffold.